Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial

Andrew R. Pettitt, Richard Jackson, Silvia Cicconi, Fotis Polydoros, Christina Yap, James Dodd, Matthew Bickerstaff, Michael Stackpoole, Umair T. Khan, Stacey Carruthers, Melanie Oates, Ke Lin, Sarah E. Coupland, Geetha Menon, Nagesh Kalakonda, Helen McCarthy, Adrian Bloor, Anna Schuh, Andrew Duncombe, Claire Dearden, Christopher Fegan, Ben Kennedy, Renata Walewska, Scott Marshall, Christopher P. Fox, and Peter Hillmen

Disclosures: ARP - Research funding: Celgene, Chugai, Gilead, GSK/Novartis, Roche, Verastem; Other remuneration: Celgene, Gilead AD - Honoraria: Abbvie, Novartis, Gilead, Janssen CY - Consultant or advisory role: Faron Pharmaceuticals; Honoraria: Celgene, Faron Pharmaceuticals MO - No conflicts of interest KL - Honoraria: Abbvie, Novartis, Gilead, Janssen SC - No conflicts of interest GM - No conflicts of interest NK - Research funding: Celgene HMcC - Consultant or advisory role: ABBVIE advisory board member Honoraria: Janssen; Other remuneration: Educational grants to attend conferences Roche, Janssen AB - Janssen – speaker, meeting attendance, advisory boards; Gilead - speaker, meeting attendance, advisory boards; Abbvie - speaker, meeting attendance, advisory boards, consultancy; GSK - advisory boards, consultancy AS - Honoraria: Gilead, Janssen, Abbvie, Roche CD - Consultant or advisory role: Advisor to Sanofi Aventis (alemtuzumab) CF - No conflicts of interest BK - No relevant conflicts of interest SM - No conflicts of interest CF - Consultant or advisory role: Abbvie, Celgene, Janssen, Gilead, Roche; Honoraria: Abbvie, Celgene, Janssen, Gilead, Roche Research funding: Abbvie, Gilead and Roche; Other remuneration: Travel and accommodation support from Abbvie, Celgene, Janssen, Gilead, Roche PH - Research funding: Janssen, Pharmacylcics, Abbvie, Roche, Gilead; Honoraria - Janssen, Abbvie, Roche; No stock, consultancy, employment conflicts RJ - No conflicts of interest UTK - Employment or leadership position: MRC Clinical Research Fellow; Research funding: UK is an MRC Clinical Training Fellow based at the University of Liverpool supported by the North West England Medical Research Council Fellowship Scheme in Clinical Pharmacology and Therapeutics, which is funded by the Medical Research Council (Award Ref. MR/N025989/1), Roche Pharma, Eli Lilly and Company Limited, UCB Pharma, Novartis, the University of Liverpool and the University of Manchester. SC - No conflicts of interest RW - Consultant or advisory role: Gilead Honoraria: Gilead, Janssen; Other remuneration: Travel grants: Janssen, Abbvie, Gilead, Takeda FP - Employment or leadership position: Novartis Pharma AG; Stock ownership: Novartis Pharma AG JD - No conflicts of interest MB - No conflicts of interest MS - No conflicts of interest RJ - No conflicts of interest
Contributions: Conception or design of the work: AP, RJ, CY, PH Data acquisition: AP, SCA, JD, MB, MS, MO, KL, SC, GM, HMCC, AB, AS, AD, CD, CF, BK, RW, SM, CF Data analysis: AP, RJ, SCI, FP Data interpretation: AP, RJ, SC, UK, NK All authors have made the following contributions: • Drafting the work or revising it critically for important intellectual content • Final approval of the version to be published • Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.